Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$32.29
+11.7%
$27.23
$15.35
$36.44
$2.97B2.262.17 million shs2.19 million shs
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$3.17
+4.3%
$2.66
$1.29
$4.54
$297.63M2.141.45 million shs1.24 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$59.53
+5.0%
$50.86
$23.30
$66.06
$3.53B2.221.47 million shs1.45 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-5.91%-5.43%+17.19%+7.24%+45.81%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
+4.83%-0.65%+13.86%+55.90%+97.40%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-6.13%-4.14%+12.93%+17.83%+57.81%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$32.29
+11.7%
$27.23
$15.35
$36.44
$2.97B2.262.17 million shs2.19 million shs
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$3.17
+4.3%
$2.66
$1.29
$4.54
$297.63M2.141.45 million shs1.24 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$59.53
+5.0%
$50.86
$23.30
$66.06
$3.53B2.221.47 million shs1.45 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-5.91%-5.43%+17.19%+7.24%+45.81%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
+4.83%-0.65%+13.86%+55.90%+97.40%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-6.13%-4.14%+12.93%+17.83%+57.81%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2.75
Moderate Buy$49.3652.85% Upside
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.57
Moderate Buy$5.4070.35% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.75
Moderate Buy$56.57-4.97% Downside

Current Analyst Ratings Breakdown

Latest EDIT, BEAM, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$55.00 ➝ $60.00
5/5/2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Boost Price TargetBuy$3.50 ➝ $4.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOutperform$50.00 ➝ $65.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
UpgradeMarket PerformOutperform$70.00
5/4/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOverweight$55.00 ➝ $65.00
4/20/2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Reiterated RatingSell (D-)
4/20/2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Reiterated RatingSell (E+)
4/14/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOverweight$50.00 ➝ $55.00
3/30/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$50.00 ➝ $55.00
3/27/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Reiterated RatingSell (D-)
3/26/2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Boost Price TargetBuy$64.00 ➝ $68.00
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$139.74M23.74N/AN/A$12.20 per share2.65
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$40.52M7.66N/AN/A$0.28 per share11.32
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M9.84N/AN/A$7.31 per share8.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$79.99M-$1.01N/AN/AN/A-57.24%-30.65%-23.73%N/A
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$160.06M-$1.89N/AN/AN/A-281.59%-545.41%-54.58%5/11/2026 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%N/A

Latest EDIT, BEAM, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.30-$0.26+$0.04-$0.26$6.37 million$2.83 million
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
3/9/2026Q4 2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.27-$0.06+$0.21-$0.06$8.77 million$24.74 million
2/24/2026Q4 2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.13$2.33+$3.46$2.33$13.22 million$114.11 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/AN/AN/AN/AN/A
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/A
13.09
13.09
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/A
3.54
3.54
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
3.37

Institutional Ownership

CompanyInstitutional Ownership
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
99.68%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
71.90%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.80%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.10%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
510102.75 million98.84 millionOptionable
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
23097.91 million95.85 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million59.42 millionOptionable

Recent News About These Companies

Twist Bioscience: Fiscal Q2 Earnings Snapshot
Twist Bioscience Q2 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Beam Therapeutics stock logo

Beam Therapeutics NASDAQ:BEAM

$32.29 +3.39 (+11.74%)
Closing price 03:59 PM Eastern
Extended Trading
$31.31 -0.99 (-3.05%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Editas Medicine stock logo

Editas Medicine NASDAQ:EDIT

$3.17 +0.13 (+4.28%)
Closing price 04:00 PM Eastern
Extended Trading
$3.16 0.00 (-0.16%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$59.53 +2.83 (+4.99%)
Closing price 04:00 PM Eastern
Extended Trading
$59.80 +0.27 (+0.46%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.